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OBJECTIVE—Some preclinical in vivo studies and limited human data suggest a possible
increasedriskofbladdercancerwithpioglitazonetherapy.Thisisaninterimreportofanongoing
cohort study examining the association between pioglitazone therapy and the risk of bladder
cancer in patients with diabetes.
RESEARCH DESIGN AND METHODS—This study includes 193,099 patients in the
Kaiser Permanente Northern California diabetes registry who were $40 years of age between
1997 and 2002. Those with prior bladder cancer were excluded. Ever use of each diabetes
medication (deﬁned as two or more prescriptions within 6 months) was treated as a time-
dependent variable. Cox regression–generated hazard ratios (HRs) compared pioglitazone use
with nonpioglitazone use adjusted for age, sex, race/ethnicity, diabetes medications, A1C, heart
failure, household income, renal function, other bladder conditions, and smoking.
RESULTS—The group treated with pioglitazone comprised 30,173 patients. There were 90
cases of bladder cancer among pioglitazone users and 791 cases of bladder cancer among non-
pioglitazone users. Overall, ever use of pioglitazone was not associated with risk of bladder
cancer (HR 1.2 [95% CI 0.9–1.5]), with similar results in men and women (test for interaction
P= 0.8). However, in the apriori categoryof .24 months of therapy, there wasan increased risk
(1.4 [1.03–2.0]). Ninety-ﬁve percent of cancers diagnosed among pioglitazone users were detected
at early stage.
CONCLUSIONS—Inthiscohortofpatientswithdiabetes,short-termuseofpioglitazonewas
not associated with an increased incidence of bladder cancer, but use for more than 2 years was
weakly associated with increased risk.
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P
eroxisomeproliferator–activatedre-
ceptor(PPAR)ghasbeendetectedin
normal uroepithelial tissue by some
but not all investigators and is generally
detectable in bladder tumors (1–3). Thia-
zolidinedione (TZD) PPARg ligands have
been shown to alter cell proliferation
rates and differentiation in human cancer
cell lines, including bladder cancer cells
(1–7).
Pioglitazone (ACTOS) is a thiazolidi-
nedione PPARg ligand used in the treat-
ment of type 2 diabetes. It is indicated as
anadjuncttodietandexercisetoimprove
glycemic control. However, it is not gen-
erally used as a ﬁrst-line therapy (8). In
preclinical studies, male rats treated with
pioglitazone developed more bladder tu-
mors than male rats treated with placebo.
This was not observed with female rats at
the same dose or with mice of either sex at
higherdoses(9).However,bladdertumors
have also been reported in laboratory ani-
mals taking experimental drugs with dual
PPARa and PPARg activity (10).
Others have reported on potential
associations between treatment with
TZDs and risk of cancer at other sites
(11–14). However, there are limited data
in humans to address this question. The
dataavailablemostlycomefromthePRO-
active study, which found a nonsigniﬁ-
cant excess of bladder tumors among
patients treated with pioglitazone (15).
In 2003, the U.S. Food and Drug Admin-
istration (FDA) requested that the manu-
facturer of pioglitazone conduct a safety
study to assess whether therapy with pio-
glitazone increases the risk of bladder
cancer. The authors of this study drafted
the initial protocol that was subse-
quently reviewed by the FDA and re-
vised accordingly. At the request of the
FDA, the study was planned to be con-
ductedover10years.Thisreportdescribes
the results of the planned midpoint in-
terim analysis.
RESEARCH DESIGN AND
METHODS
Data source
Kaiser Permanente Northern California
(KPNC) provides comprehensive health
careservices toapproximately3.2million
members, representing approximately
30% of the population of the geographic
area (16). The KPNC pharmacy database
includes information on each outpatient
prescription dispensed at a KPNC phar-
macy.Approximately95% ofKPNC mem-
bers with pharmacy beneﬁts ﬁll all of their
prescriptions at KPNC pharmacies (16).
The source population was identiﬁed
from the KPNC diabetes registry. The di-
abetes registry gathers data from various
componentsoftheKPNCelectronicmed-
ical record (EMR) and related clinical
databases to build and follow the registry
cohort across time. These data include
cancer registries, pharmacy records, lab-
oratory records, and inpatient and out-
patient medical diagnoses. The registry
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ORIGINAL ARTICLEidentiﬁes patients with diabetes primarily
from four data sources: primary hospital
discharge diagnoses of diabetes, two or
more outpatient-visit diagnoses of diabe-
tes, any prescription of a diabetes-related
medication,oranyrecordofA1C.6.7%.
These data have beenwidelyusedinprior
epidemiology studies (16).
Patients were eligible for the overall
study cohort if they met any of the
following criteria: 1)a so f1J a n u a r y
1997, they had been diagnosed with di-
abetes, were age $40 years and were
members of KPNC; 2) they had been di-
agnosed with diabetes, reached age 40
years between 1 January 1997and 31De-
cember 2002, and were KPNC members
on their 40th birthday; or 3)t h e yh a dd i -
abetes and were age $40 years when they
joined KPNC between 1 January 1997
and 31 December 2002. From this cohort
of 207,389, we excluded 823 patients
with a diagnosis of bladder cancer prior
to entry in the cohort or within 6 months
of joining KPNC to avoid misclassiﬁcation
ofprevalentbladdercancers asincident di-
agnoses. Likewise, patients without pre-
scription beneﬁts at the time of entry into
the cohort (n = 6,674) or those with a gap
of .4 months in prescription or member-
ship beneﬁts where the gap started within
the ﬁrst 4 months of entering the cohort
(n = 6,782) were excluded. This analysis
included data from 1 January 1997 to
30 April 2008.
Exposure deﬁnition
Ever use of a diabetes medication was
deﬁned as having ﬁlled at least two pre-
scriptions for the drug within a 6-month
period according to the KPNC pharmacy
database. Diabetes medications were cate-
gorized as pioglitazone, other TZDs, met-
formin,sulfonylureas,insulin,andother
(e.g., miglitol and acarbose). Separate
indicator variables were created for
patients who had not received any di-
abetes medication prescriptions and for
thosewho receivedatleastoneprescrip-
t i o nb u th a dn o tm e tt h ed e ﬁnition of
exposure.
Time since initiation of pioglitazone
wascalculatedbycountingtheinterval,in
days, since the date of the second piogli-
tazoneprescription.Cumulative duration
ofexposuretopioglitazonewasmeasured
by counting the number of days between
prescriptions. If the next prescriptionwas
ﬁlled within 30 days of the expected end
date of the previous prescription, we
assumed that therapy was uninterrupted.
However, if there were no reﬁlls within
the 30 days after the expected end date of
the previous prescription, we assumed a
gap in therapy starting 30 days after the
datethatthepreviousprescriptionshould
have ended. The cumulative duration
variable was a time-varying sum of all
periods of exposure even if there were
gaps in treatment.
Cumulative dose of pioglitazone was
calculated in a similar fashion. For any
prescriptionthatwascompletedpriortoan
event date, the total prescribed dose (i.e.,
number of pills in the prescription multi-
plied by the dose of the pills) was assumed
to have been consumed. For prescriptions
thatwerestillactiveonthedateofanevent,
the total consumed dose was reduced to
reﬂect the proportion of pills expected to
have been consumed by that date.
Primary outcome
Follow-upstartedontheﬁrstdatethatthe
inclusion criteria were met. Follow-up
ended on 30 April 2008 or when any of
the following occurred:1)agapofgre ate r
than 4 months in either membership or
prescription beneﬁts, 2) a new diagnosis
of bladder cancer, or 3) death from any
cause.
Incident bladder cancers were identi-
ﬁed from the KPNC cancer registry, one
of several sites that submit data to the
Surveillance, Epidemiology, and End Re-
sults (SEER) program, from 1 January
1997 to 30 April 2008. This was supple-
mented by case identiﬁcation through
surveillance of electronic pathology re-
ports within KPNC from 1 January 2005
to 30 April 2008. We did not make any
distinction regarding the histology of the
bladder cancer and included patients di-
agnosed with in situ bladder cancer and
papillary urethral neoplasm of low malig-
nant potential from 2005 onward (17,18).
Cancer stage was categorized according to
SEER guidelines as local, regional, distant,
or undetermined.
Confounder variables
Variables considered as potential con-
founders are included in Table 1. Data
on potential confounders were extracted
from the EMR. Possible confounders,
such as congestive heart failure, were
identiﬁed by searching the related ICD-9
codes in the hospital and outpatient data-
bases. Other confounders, such as renal
insufﬁciency and glycemic control, were
identiﬁed in the clinical laboratory data-
base. Demographic variables were identi-
ﬁed from administrative data. For smoking
and duration of diabetes, the EMR data
were supplemented with data from mem-
ber surveys. We selected as potential con-
foundersvariablesbelievedtobeassociated
withone ormore ofthe following: the risk
of bladder cancer (e.g., age, race, sex,
smoking, and socioeconomic status), the
possibility of detection of bladder cancer
(e.g., urinary diseases or symptoms, in-
cluding urinary tract infections, urinary in-
continence, urolithiasis, and prior history
ofothercancers),orthelikelihoodofbeing
prescribed pioglitazone (e.g., diabetes du-
ration, A1C levels, congestive heart failure,
and renal insufﬁciency). With the excep-
tionofsmoking,allconfoundersweremea-
sured using data recorded on or before the
start of follow-up.
Nested case-control study
Because of incomplete or missing EMR
data on potential confounders including
race/ethnicity, smoking history, duration
of diabetes, and occupational exposures,
we supplemented the cohort study with a
case-control study nested within the
study cohort to assess whether there was
residual confounding by these variables
in the cohort study. From the source
cohort, we identiﬁed all incident diagno-
ses of bladder cancer from 1 October
2002 to 30 April 2008. The index date
was deﬁned as the date of bladder cancer
diagnosis.
For each individual with bladder can-
cer, one control was randomly selected
after matching for sex, age (62.5 years),
and time from entry into the KPNC dia-
betesregistryto indexdate (66mo nths).
In addition, no control subjects could
be diagnosed with bladder cancer or
be censored from the cohort for other
r e a s o n sa so ft h ed a t eo fﬁrst diagnosis
with bladder cancer of the matched case
subject.
Thedatethatthecasesubjectwasﬁrst
diagnosed with bladder cancer served as
the reference date for both the case sub-
ject and the matched control. The addi-
tionaldataforthecase-controlstudy(e.g.,
duration of diabetes, smoking, use of
indwellingcatheters,frequencyofurinary
tract infections, and occupational expo-
sures) were collected up to the reference
datethroughtelephoneinterviewsusinga
standardized questionnaire administered
by trained interviewers.
Statistical analyses
Continuous and categorical variables
were compared with the Wilcoxon rank-
sum test and x
2 test or Fisher’se x a c tt e s t ,
respectively. Exposure to pioglitazone
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cations were treated as unidirectional
time–dependent variables; i.e., all follow-
up time from entry into the cohort until
the date that the patient ﬁrst met the def-
inition of ever use was attributed to the
never-use group and once a patient met
the deﬁnition of ever use the patient was
considered exposed from that point for-
ward, even if the patient discontinued
the medication. Cox proportional hazards
models were used for all calculations of
the hazard ratio (HR) of bladder cancer
with pioglitazone, adjusted for the covari-
ates. The reference group for calculation
of the HR associated with ever use of pio-
glitazone (with or without other diabetes
medications) was never use of pioglita-
zone at that point of time, which by deﬁ-
nition included those treated with any
diabetes medications other than pioglita-
zone and those with only dietary therapy.
Identical methods were used to determine
relative HRs associated with exposure to
other categories of diabetes medications.
Because the large number of cases of blad-
der cancer made overﬁtting the statistical
model unlikely, we included all potential
confounders listed in Table 1 in the fully
adjusted Cox regression models for ever
exposure.
Analysis of the case-control study
was conducted in a similar fashion ex-
cept that conditional logistic regression
was used to calculate odds ratios (ORs)
(95% CIs).
RESULTS—After application of the ex-
clusion criteria, the ﬁnal cohort included
193,099 patients with diabetes. Patients
who ever used pioglitazone during the
study period (n = 30,173) were less likely
to be age $70 years and were more likely
t oh a v eab a s e l i n eA 1 C.10% than pa-
tientswhonever used pioglitazone(Table
1). They were also more likely to have
been treated with metformin, sulfonyl-
ureas, and insulin prior to, after, or along
with pioglitazone. Among patients who
ever used pioglitazone, the median time
from the ﬁrst prescription to the end of
follow-up was 3.3 years (range 0.2–8.5
years), and the median duration of ther-
apy among pioglitazone-treated patients
was 2.0 years (0.2–8.5 years) (Table 1).
The median follow-up time from cohort
entry was 6.2 years (0.1–11.3) in those
never treated with pioglitazone and 9.3
years (0.1–11.3) in those ever exposed
to pioglitazone (including follow-up
before, during, and after pioglitazone
therapy).
Table 1—Demographics of the study cohort according to ever use of pioglitazone:
the KPNC diabetes registry, 1997–2008
Ever use of
pioglitazone*
Never use of
pioglitazone*
N 30,173 162,926
Age (years)
40–49 8,612 (28.5) 36,452 (22.4)
50–59 9,945 (33.0) 41,962 (25.8)
60–69 7,799 (25.8) 42,691 (26.2)
$70 3,817 (12.7) 41,821 (25.7)
Sex (female) 14,157 (46.9) 75,686 (46.5)
Race/ethnicity
White 14,768 (48.9) 80,777 (49.6)
Black 2,823 (9.4) 16,731 (10.3)
Asian 3,834 (12.7) 18,877 (11.6)
Hispanic 3,320 (11.0) 14,430 (8.9)
Other 1,691 (5.6) 8,876 (5.4)
Missing 3,737 (12.4) 23,235 (14.3)
Current smoker 6,052 (20.1) 28,023 (17.2)
Renal function
Normal creatinine 23,174 (76.8) 125,879 (77.3)
Elevated creatinine† 1248 (4.1) 13,993 (8.6)
Missing 5,751 (19.1) 23,054 (14.2)
Bladder condition‡ 3,686 (12.2) 25,581 (15.7)
Congestive heart failure 969 (3.2) 11,038 (6.8)
Income
Low§ 14,413 (47.8) 82,270 (50.5)
High 12,825 (42.5) 66,133 (40.6)
Missing 2,935 (9.7) 14,523 (8.9)
Baseline A1C (%)
,7 4,873 (16.2) 46,407 (28.5)
7–7.9 5,455 (18.1) 31,517 (19.3)
8–8.9 3,921 (13.0) 17,060 (10.5)
9–9.9 2,979 (9.9) 11,524 (7.1)
$10 7,330 (24.3) 28,017 (17.2)
Missing 5,615 (18.6) 28,401 (17.4)
Newly diagnosed with diabetes at the start of
follow-up¶ 14,687 (48.7) 94,739 (58.1)
Duration of diabetes (years)
0–5 17,363 (57.5) 102,916 (63.2)
5–9 2,983 (9.9) 9,671 (5.9)
$10 2,956 (9.8) 17,432 (10.7)
Missing 6,871 (22.8) 32,907 (20.2)
Other cancer prior to baseline 1,186 (3.9) 8,762 (5.4)
Other diabetes medications
Other TZDs 2,754 (9.1) 2,470 (1.5)
Metformin 24,797 (82.2) 70,956 (43.6)
Sulfonylureas 26,311 (87.2) 95,429 (58.6)
Other oral hypoglycemic drugs 1,482 (4.9) 1,865 (1.1)
Insulin 13,123 (43.5) 41,337 (25.4)
Pioglitazone use during follow-up
Time since starting pioglitazone (months) 39.5 (1–102) N/A
,18 7,245 (24.0) N/A
18–36 6,681 (22.1) N/A
.36 16,247 (53.8) N/A
Duration of therapy (months) 24.1 (1–102) N/A
,12 7,332 (24.3) N/A
12–24 7,677 (25.4) N/A
.24 15,164 (50.3) N/A
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Pioglitazone therapy and the risk of bladder cancerDuring the follow-up period, there
were 881 cases of newly diagnosed blad-
der cancer cases: 90 among patients who
ever used pioglitazone and 791 among
patients who never used pioglitazone.
The unadjusted bladder cancer incidence
rates per 100,000 person-years for ever
use of pioglitazone and never use of pio-
glitazone were 81.5 and 68.8, respectively.
By comparison, in SEER, the annual in-
cidenceper100,000person-yearsinthose
aged $50 years ranged from 70.6 to 75.3
during the years 2000–2007 (19). After
adjustment for only age, sex, and use of
other categories of diabetes medications,
there was a slightly elevated but not sig-
niﬁcant association of ever use of pioglita-
zone with bladder cancer risk (HR 1.2
[95% CI 0.9–1.5]). The fully adjusted
model provided nearly identical results
(Table 2). The pioglitazone use–bladder
cancer association did not differ by sex
(men 1.1 [0.9–1.5)] and women 1.4 [0.8–
2.6];testforinteractionP=0.81).Analyses
from the case-control study revealed the
absence of residual confounding due to
variables that were incompletely measured
(smoking and race/ethnicity) or not mea-
sured (occupation) in the cohort study
(data not shown).
When we examined the association
between bladder cancer incidence and
increasing levels of pioglitazone exposure
(Table 2), the risk of bladder cancer
slightly increased with increasing dose
and duration of pioglitazone use. After
adjustment for only age and sex, the risk
of bladder cancer was 30% higher among
those whose duration of pioglitazone
therapy was 12–24 months (HR 1.3
[95% CI 0.9–2.0]) and 50% higher
among those with .24 months of expo-
sure(1.5[1.1–2.0])thanthatamongnever
users of pioglitazone. The fully adjusted
models provided similar results (.24
months of exposure 1.4 [1.03–2.0]).
There were no clear patterns between in-
creasing time since initiation of pioglita-
zone and bladder cancer risk.
Among men, after adjustment for age
there was a signiﬁcant increase in the
relative hazard of bladder cancer with
more than 24 months of exposure (HR 1.6
[95%CI1.2–2.3])andwitha.28,000-mg
cumulative dose (1.8 [1.2–2.6]). Because
there were only 14 women treated with
pioglitazone who were diagnosed with
bladder cancer, estimates of dose and du-
ration were unstable and are not reported.
In a post hoc analysis to assess
whether the increased incidence of blad-
der cancer was greater with even longer
duration of exposure, we further subdi-
vided the category of .24 months of ex-
posure. This analysis demonstrated an
additional increase in the relative hazard
of bladder cancer with longer duration of
therapy. Among 6,670 patients with .48
monthsofpioglitazoneexposure,theage-
and sex-adjusted HR was 1.7 (95% CI
1.1–2.9), and the fully adjusted hazard
ratio was 1.6 (0.96–2.7). The age- and
sex-adjusted point estimates compared
with those of unexposed subjects went
from 0.8 for ,12 months of use to 1.3 for
12–24 months, 1.3 for 24–36 months,
1.5 for 36–48 months, and 1.7 for .48
months (test for trend treating duration of
exposure as an ordinal variable with levels
0 [no exposure] to 5 [.48 months of ex-
posure], P = 0.01 in age- and sex-adjusted
and P = 0.02 in fully adjusted models).
There were proportionately more in
situ cancers among the pioglitazone users
(data not shown). Only 3% of bladder
cancers in the patients who ever used
pioglitazone were of regional or advanced
stage at the time of diagnosis. In contrast,
9% of bladder cancers in the patients who
never used pioglitazone had regional or ad-
vancedstagediseaseatthetimeofdiagnosis
(two-sidedFisher’sexactP=0.10excluding
2% of pioglitazone-exposed cancers and
4% of nonpioglitazone-exposed cancers
with undetermined stage).
CONCLUSIONS—We describe the
interimresultsofanongoingcohortstudy
beingconductedattherequestoftheFDA
in response to animalstudiessuggesting a
possible increased risk of bladder cancer
among patients treated with pioglitazone.
This association was initially observed in
male rats but not in female rats or in mice
of either sex (9). Subsequent research
suggested that this effect in male rats can
be prevented with dietary modiﬁcation,
suggesting a mechanism related to the
bladder anatomy and acid milieu of urine
in male rats (20). However, a more recent
studyinadifferentanimalmodel,hydroxy-
butyl(butyl)nitrosamine (OH-BBN), pro-
posed that rosiglitazone, another TZD,
may be a tumor promoter even in late
stages of bladder cancer development
(21). At the time of this interim report,
we did not observe a signiﬁcant associa-
tion between any pioglitazone exposure
and bladder cancer risk in our cohort
study overall. However, we observed an
increased risk of bladder cancer among
patients with the longest exposure to pio-
glitazone.Aposthocanalysissuggestsfur-
ther increased risk with even longer
exposure periods. Finally, there was no
evidence of a stage shift to more advanced
bladder cancer among the pioglitazone-
exposed patients.
There are several major strengths of
this study. The KPNC diabetes registry
includes a large population of individuals
with diabetes. The diabetes registry uses
active surveillance based on diagnoses,
laboratory tests, and pharmacy data and
as such is also able to identify individuals
with diabetes who are not treated with
medications. We used the KPNC cancer
registry to identify patients with bladder
cancer. The cancer registry, which con-
tributes data to SEER, is held to SEER’s
very high quality standards. Another
strength is the availability of the KPNC
pharmacy data. By requiring patients to
ﬁll two prescriptions within a 6-month
period, we have minimized misclassiﬁca-
tion of unexposed patients as exposed.
Patients who ﬁlled only a single pioglita-
zoneprescription(n=4,679)orwhoﬁlled
two or more prescriptions that were never
within 6 months of each other (n =5 8 0 )
werenotcategorizedasexposedaccording
to our deﬁnition. Some of these patients
may have actually been exposed to piogli-
tazone. However, this misclassiﬁcation is
Table 1—Continued
Ever use of
pioglitazone*
Never use of
pioglitazone*
Cumulative dose (mg) 17,670 (450–179,000) N/A
1–10,500 10,281 (34.1) N/A
10,501–28,000 9,667 (32.0) N/A
.28,000 10,225 (33.9) N/A
Dataaren(%)ormedian(range)unlessotherwiseindicated.N/A,notapplicable.*AllcomparisonshavePvalues
,0.01 except female sex (P = 0.46). †Creatinine$1.4 mg/dL for women and $1.5mg/dLfor men. ‡History
of urinary tract infections, urolithiasis, incontinence, and other bladder or urethralconditions. §Low income
deﬁned as median household income in census block below the cohort average ($59,000). ¶Includes newly
diagnosed patients and patients who newly enrolled in KPNC with an existing diagnosis of diabetes.
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a small duration of therapy would be
unlikely to change the risk of cancer. Fur-
thermore, because these patients repre-
sented a small proportion of those who
ﬁlledatleastonepioglitazoneprescription
and an even smaller proportion of the
population categorized as unexposed,
their potential impact on the estimated
HR is limited. Finally, the large number
of patients who have been prescribed pio-
glitazone and that .50% of these have
taken the medication for .2 years are ma-
jor strengths of the study.
Considering potential limitations,
our cohort study had incomplete or miss-
ing data on several variables known to be
associated with bladder cancer, such as
smoking and occupational exposures.
However, our nested case-control study
demonstrated that these unmeasured or
incompletely measured confounders
known to be associated with bladder
cancer were unlikely to have inﬂuenced
our cohort study results. In addition, in
the case-control analysis we were able to
more precisely categorize smoking ac-
cording to cumulative exposure in pack-
years. Despite this, smoking was not a
confounder of the pioglitazone-bladder
cancer analysis. Our analysis of the stage
of cancer allows us to consider the po-
tential for detection bias. Stage at diagno-
sis of bladder cancer was not signiﬁcantly
different between the pioglitazone-
treated patients and those not treated
withpioglitazone.However,therewerepro-
portionately more in situ cancers among
t h ep i o g l i t a z o n eu s e r s .T h i sm i g h tb e
observed if pioglitazone-treated patients
underwent greater surveillance for blad-
der cancer or if pioglitazone increases the
risk of bladder cancer by its effect on the
early stages of development. To account
forthepossibilityofincreased surveillance,
weadjustedforrecordedbladderconditions
that might prompt increased testing.
Furthermore,wecannotdeterminewhether
therewerepatientswithundiagnosedblad-
der cancer at the start of follow-up. How-
ever, this should not have been differential
between those who did and those who did
not receive treatment with pioglitazone.
Further, the positive associations that we
observed were with long-term exposure.
Therefore,itisunlikelythatthiswouldbe
explained by an imbalance in prevalent
yet undiagnosed cancer at the time of
cohort entry.
Eightpercentofpatientseverexposed
to pioglitazone were documented to have
received their ﬁrst prescription within 4
months of entry into the cohort. For this
small group, we may have underesti-
matedthecumulativedurationofexposure.
However, this would potentially over-
estimate the relative risk of short- and
intermediate-term exposure if long-term
use of pioglitazone is associated with an
increased risk of bladder cancer. Thus,
any misclassiﬁcation from this left censor-
ing is unlikely to have changed the results.
Although several studies have sug-
gested an increased risk of bladder cancer
among patients with diabetes irrespective
of medication exposure (22), there are
l i m i t e dc o n t r o l l e dd a t ao nt h er e l a t i v e
risk of bladder cancer among patients
treated with pioglitazone. The PROactive
study included 2,605 patients treated
with pioglitazone and 2,633 treated with
placebo, and there was a nonsigniﬁcant
excess of bladder tumors among patients
treated with pioglitazone (14 vs. 6) (15).
In that study, average follow-up time was
34.5 months, yet much of the excess in
bladder cancer incidence (eight pioglita-
zone versus three placebo) occurred in
the ﬁrst year of follow-up. After the ﬁrst
year, there were six cases of cancer in
the pioglitazone arm versus three in the
placebo arm. In 4 years of observational
follow-upofthePROactivepopulationaf-
tertheendoftherandomizedphaseofthe
study, the relative incidence of bladder
cancer among the patients treated with
pioglitazoneduringtheinitialclinicaltrial
phase has not increased further. How-
ever, most subjects did not receive any
TZDs during the observational follow-
up period (I. Ahmad, personal communi-
cation).Inourstudy,theHRswere0.8for
Table 2—Incidence rate and HR of bladder cancer with pioglitazone use: the KPNC diabetes registry, 1997–2008
Median (range) bladder
cancer incidence rate
(per 100,000 person-years)
HR (95% CI)
adjusted
for age and sex
Fully adjusted
HR (95% CI)*
Never use of pioglitazone 68.8 (64.1–73.6) Ref. Ref.
Ever use of pioglitazone† 81.5 (64.7–98.4) 1.2 (0.9–1.5)‡ 1.2 (0.9–1.5)
Time since starting pioglitazone (months)†
,18 67.1 (41.8–92.4) 1.1 (0.8–1.6) 1.2 (0.8–1.7)
18–36 85.2 (51.8–118.6) 1.3 (0.9–2.0) 1.4 (0.9–2.1)
.36 93.1 (63.5–122.7) 1.3 (0.9–1.8) 1.3 (0.9–1.8)
Ptrend — 0.04 0.07
Duration of therapy (months)†
,12 48.4 (29.0–67.8) 0.8 (0.5–1.2) 0.8 (0.6–1.3)
12–24 86.7 (52.0–121.4) 1.3 (0.9–2.0) 1.4 (0.9–2.1)
.24 102.8 (71.7–133.8) 1.5 (1.1–2.0) 1.4 (1.03–2.0)
Ptrend — 0.02 0.03
Cumulative dose (mg)†
1–10,500 59.7 (39.0–80.4) 1.0 (0.7–1.4) 1.0 (0.7–1.5)
10,501–28,000 76.8 (48.3–105.2) 1.1 (0.8–1.6) 1.2 (0.8–1.8)
.2,8000 105.9 (68.0–143.8) 1.5 (1.1–2.2) 1.4 (0.96–2.1)
Ptrend — 0.05 0.08
*IncludesallpotentialconfounderslistedinTable1inthestatisticalmodel.†NeveruseofpioglitazonewasthereferencegroupforthecalculationoftheHRassociated
with ever use of pioglitazone and time, duration, and dose of pioglitazone use. ‡Also adjusted for use of other diabetes medications.
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.2 years of therapy. In a post hoc analy-
sis, the HR was even higher for those with
.36 months of exposure and .48
months of exposure, with a signiﬁcant
test for trend for increasing risk with in-
creasing duration of exposure. Although
theselongerdurationswerenotstatistically
signiﬁcant in the fully adjusted models,
this may have been due to low statistical
power because the results were similar to
the age- and sex-adjusted model. A recent
observational cohort study using claims
data did not observe an increased risk of
bladder cancer with TZD exposure. How-
ever, that study was limited by a small
number of bladder cancer cases and reli-
ance on administrative data to establish
the diagnosis of bladder cancer, did not
distinguish between pioglitazone and ro-
siglitazone, and, perhaps most impor-
tantly, did not report data on duration of
exposure (11).
Itispossiblethatany increasedrisk of
bladder cancer observed with pioglita-
zone could be attributed to other diabetes
medications that reduce the risk of blad-
der cancer. Some research suggests that
metformin use is associated with a re-
duced risk for various cancers (23,24);
others have suggested that insulin use
might increase the risk of cancer (24,25).
However, we did not observe any associ-
ation between ever use of other diabetes
medications and bladder cancer risk. In
addition, we could not compare pioglita-
zone with other TZDs because there had
been little use of the latter in this cohort.
In summary, we did not observed a
statistically signiﬁcant increased risk of
bladder cancer among patients treated
with pioglitazone for ,2 years. However,
the analyses addressing increasing expo-
sure to pioglitazone observed a weak in-
creased risk with longer-term therapy.
Additional follow-up is planned to ex-
plore this association. Regardless, it is re-
assuring that only 3 of the 90 patients
diagnosed with bladder cancer and treated
with pioglitazone were at advanced stage.
Acknowledgments—This study was funded
by a grant from Takeda Global Research &
Development Center, Inc. The sponsor was
given the opportunity to review and comment
on the manuscript before submission. How-
ever, the opinions expressed are those of the
authors. J.D.L. reports receipt of other research
fundingfrom Takeda and GlaxoSmithKline and
having served as a consultant to Takeda and to
GlaxoSmithKline. A.F. reports having received
additional research funding from Takeda and
Lilly. B.L.S. reports receipt of research funding
from Takeda and having served as a consultant
to GlaxoSmithKline and Lilly. No other poten-
tial conﬂicts of interest relevant to this article
were reported.
J.D.L. and A.F. designed the study, in-
terpreted data, and drafted and edited the
manuscript. T.P. collected, analyzed, and in-
terpreted data and edited the manuscript.
M.H.collected,analyzed,andinterpreteddata;
edited the manuscript; and provided adminis-
trative support. W.B.B., C.P.Q., and D.J.V. de-
signed the study, interpreted data, and edited
the manuscript. L.N. interpreted data, edited
the manuscript, and provided administrative
support. J.S. and B.L.S. designed the study, in-
terpreted data, and edited the manuscript.
References
1. Yoshimura R, Matsuyama M, Segawa Y,
etal.Expressionofperoxisomeproliferator-
activated receptors (PPARs) in human
urinary bladder carcinoma and growth
inhibition by its agonists. Int J Cancer
2003;104:597–602
2. NakashiroKI,HayashiY,KitaA,etal.Role
ofperoxisomeproliferator-activatedreceptor
gammaanditsligandsinnon-neoplasticand
neoplastic human urothelial cells. Am J
Pathol 2001;159:591–597
3. Guan YF, Zhang YH, Breyer RM, Davis L,
Breyer MD. Expression of peroxisome
proliferator-activated receptor gamma
(PPARgamma) in human transitional
bladder cancer and its role in inducing
cell death. Neoplasia 1999;1:330–339
4. Tontonoz P, Singer S, Forman BM, et al.
Terminal differentiation of human lipo-
sarcoma cells induced by ligands for
peroxisome proliferator-activated receptor
gamma and the retinoid X receptor.
Proc Natl Acad Sci USA 1997;94:
237–241
5. Kubota T, Koshizuka K, Williamson EA,
et al. Ligand for peroxisome proliferator-
activated receptor gamma (troglitazone)
haspotentantitumoreffectagainsthuman
prostate cancer both in vitro and in vivo.
Cancer Res 1998;58:3344–3352
6. Ohta K, Endo T, Haraguchi K, Hershman
JM, Onaya T. Ligands for peroxisome
proliferator-activated receptor gamma
inhibit growth and induce apoptosis of
human papillary thyroid carcinoma
cells. J Clin Endocrinol Metab 2001;86:
2170–2177
7. Elstner E, Müller C, Koshizuka K, et al. Li-
gandsfor peroxisome proliferator-activated
receptorgamma and retinoic acid receptor
inhibit growth and induce apoptosis of
human breast cancer cells in vitro and in
BNX mice. Proc Natl Acad Sci USA 1998;
95:8806–8811
8. Nathan DM, Buse JB, Davidson MB, et al.;
American Diabetes Association; European
Associationfor StudyofDiabetes.Medical
management of hyperglycemia in type 2
diabetes: a consensus algorithm for the
initiation and adjustment of therapy:
a consensus statement of the American
Diabetes Association and the European
Association for the Study of Diabetes.
Diabetes Care 2009;32:193–203
9. Takeda Pharmaceuticals America, Inc.
Actos (Pioglitazone Hydrochloride) Tablets:
Full Prescribing Information. 2009; Avail-
able from http://www.actos.com/actospro/
home.aspx. Accessed 26 August 2010
10. Cohen SM. Effects of PPARgamma and
combined agonists on the urinary tract of
rats and other species. Toxicol Sci 2005;
87:322–327
11. Oliveria SA, KoroCE, Yood MU,Sowell M.
Cancer incidence among patients treated
with antidiabetic pharmacotherapy. Di-
abetes & Metabolic Syndrome: Clinical
Research & Reviews 2008;2:47–57
12. Govindarajan R, Ratnasinghe L, Simmons
DL, et al. Thiazolidinediones and the risk
of lung, prostate, and colon cancer in
patients with diabetes. J Clin Oncol 2007;
25:1476–1481
13. Koro C, Barrett S, Qizilbash N. Cancer
risks in thiazolidinedione users compared
to other anti-diabetic agents. Pharmaco-
epidemiol Drug Saf 2007;16:485–492
14. Monami M, Lamanna C, Marchionni N,
Mannucci E. Rosiglitazone and risk of
cancer: a meta-analysis of randomized
clinical trials. Diabetes Care 2008;31:
1455–1460
15. DormandyJA,CharbonnelB, Eckland DJ,
et al. Secondary prevention of macro-
vascular events in patients with type 2 di-
abetes in the PROactive Study (PROspective
pioglitAzone ClinicalTrial In macroVascular
Events): a randomised controlled trial. Lan-
cet 2005;366:1279–1289
16. FriedmanG,HabelL,BolesM,McfarlandB.
KaiserPermanenteMedicalCareProgram:
DivisionofResearch,NorthernCalifornia,
and Center for Health Research, North-
west Division. In Pharmacoepidemiology.
3rd ed. Strom BL, Ed. West Sussex, U.K.,
John Wiley & Sons, 2000, p. 263–283
17. Samaratunga H, Makarov DV, Epstein JI.
Comparison of WHO/ISUP and WHO
classiﬁcation of noninvasive papillary
urothelialneoplasmsforriskofprogression.
Urology 2002;60:315–319
18. Cheng L, Neumann RM, Bostwick DG.
Papillary urothelial neoplasms of low ma-
lignant potential. Clinical and biologic im-
plications. Cancer 1999;86:2102–2108 [see
comment]
19. Surveillance Epidemiology and End Results
Fast Stats. 2010. National Cancer Institute,
Rockville, MD; Available from http://seer.
cancer.gov/faststats/. Accessed 26 August
2010
20. Dominick MA, White MR, Sanderson TP,
et al. Urothelial carcinogenesis in the uri-
nary bladder of male rats treated with
muraglitazar, a PPAR alpha/gamma ago-
nist: evidence for urolithiasis as the
care.diabetesjournals.org DIABETES CARE, VOLUME 34, APRIL 2011 921
Lewis and Associatesinciting event in the mode of action.
Toxicol Pathol 2006;34:903–920
21. LubetRA,FischerSM,SteeleVE,JulianaMM,
Desmond R, Grubbs CJ. Rosiglitazone, a
PPAR gamma agonist: potent promoter of
hydroxybutyl(butyl)nitrosamine-induced
urinary bladder cancers. Int J Cancer
2008;123:2254–2259
22. Larsson SC, Orsini N, Brismar K, Wolk A.
Diabetes mellitus and risk of bladder can-
cer: a meta-analysis. Diabetologia 2006;49:
2819–2823
23. Evans JM, Donnelly LA, Emslie-Smith
AM,AlessiDR,MorrisAD.Metforminand
reducedriskofcancerindiabeticpatients.
BMJ 2005;330:1304–1305
24. Giovannucci E, Harlan DM, Archer MC,
et al. Diabetes and cancer: a consensus
report. CA Cancer J Clin 2010;60:
207–221
25. Currie CJ, Poole CD, Gale EA. The in-
ﬂuence of glucose-lowering therapies on
cancer risk in type 2 diabetes. Dia-
betologia 2009;52:1766–1777
922 DIABETES CARE, VOLUME 34, APRIL 2011 care.diabetesjournals.org
Pioglitazone therapy and the risk of bladder cancer